boceprevir Articles
Hepatitis C market rivals Merck & Co and Roche in marketing pact for newly-approved boceprevir
18 May 2011
Vertex maintains 2010 outlook, reveals launch plan for hep C drug telaprevir and progress of other programs
11 January 2011
Liver disease meeting hears updates on Merck & Co’s boceprevir, Boehringer Ingelheim’s HCV combo, Vertex’ telaprevir and Gilead’s Viread
2 November 2010
Showing 1-5 of 5 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
